spontaneous inhibitors of factor viii (antihemophilic factor)

Heterogeneity of human circulating anticoagulants against antihemophilic factor (factor VIII).

The heterogeneity of human circulating anticoagulants against antihemophilic factor (AHF, factor VIII) observed in seven patients, both with and without classic hemophilia, was investigated by neutralization of their activity with antiserums directed to whole IgG and to lambda and kappa light chains. All seven anticoagulants were immunoglobulins. Six appeared to contain both kinds of light chai...

Detection of Factor VIII Inhibitors in Hemophilia A Patients

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

FIXing factor VIII inhibitors.

2007;25(11):1315-1321. 6. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495. 7. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 20...

The Relationship of the Properties of Antihemophilic Factor ( Factor VIII ) That Support Ristocetin - Induced Platelet Agglutination

A monoclonal antibody to human antihemophilic factor (AHF. factor VIII) was derived from BALB/c mouse spleen cells fused with P3x63Ag8 mouse plasmacytoma cells. This antibody. harvested from culture medium or ascites fluid. reacted with purified AHF and with plasmas from normal subjects or classic hemophiliacs, as measured by enzymelinked immuonsorbant assay (ELISA). but not with plasmas from p...

Is there a precursive, relatively procoagulant-inactive form of normal antihemophilic factor (factor VIII)?

When factor VIII/von Willebrand factor (FVIII/vWF) is chromatographed on 4% agarose in 0.25 M CaCI2. the procoagulant activity partially separates from the void volume protein peak. If FVIII/vWF is reacted with thrombin prior to chromatography, both the magnitude and resolution of the proe.oagulant activity peak are greatly increased. These observations suggest that activated species of FVIII/v...

The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans.